CRB-913

all catalysts(0)

nothing on the calendar yet

News(2)

• FDA clears first generic radioligand drug; Sionna turns to layoffs
  A Lutathera copycat has become the first “radioligand equivalent” cleared by regulators. Elsewhere, Novo dropped the “Nordisk” from its name and a novel RNAi drug showed early promise.
  biopharma_dive · 15d ago
• Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
  Corbus Pharmaceuticals’ phase 1b obesity trial has generated evidence that its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The…
  fiercebiotech · 17d ago